Asian Currencies Stay Range-Bound as Investors Eye China Data, RBNZ Outlook and U.S.-Iran Ceasefire 
Central Banks Eye Gold, Reduce Dollar Exposure as AI Adoption Accelerates: OMFIF Survey 
Michael Burry Shorts Tesla at $416 as AI and Semiconductor Bearish Bets Expand 
RBA Minutes Signal Australia Central Bank Remains Ready to Raise Interest Rates if Inflation Persists 
Europe Heatwave Creates Growth Opportunity for Carrier, Trane, and Johnson Controls, Citi Says 
Apple Challenges India Antitrust Probe, Says CCI Copied Rivals’ Claims in App Store Case 
Asian Stocks End Strong Quarter as Dollar Surges, Yen Hits 40-Year Low Ahead of US Jobs Data 
Baige Online Shares Soar 333% in Hong Kong IPO Debut as AI Insurance Demand Lifts Chinese Listings 
Australia Sues Amazon Over Prime Video Ads and Subscription Terms 
Global Financial Firms Shift Asia Expansion Focus to South Korea as China, India Face Caution 
Trump Urges Gasoline Retailers to Cut Prices to $2.50 Per Gallon, Warns of Legal Action 
Argentina Economy Shrinks 1.5% in April, Recovery Under Milei Loses Momentum 
Dollar Slips Ahead of Key U.S. Jobs Data as Fed Rate Outlook, ECB, and Iran Talks Shape Forex Markets 
Oil Prices Slip as U.S.-Iran Peace Talks and Strait of Hormuz Risks Keep Markets on Edge 
SoftBank Shares Slide as OpenAI IPO Delay Concerns Weigh on AI Investment Outlook 
Gold Prices Drop as Fed Rate Outlook and Iran Tensions Weigh on Market 
Novartis AG is a Switzerland-based pharmaceutical company that ranks in the top 5 largest pharma brands in the world. It has recently acquired the American biotech firm, Chinook Therapeutics, for $3.5 billion.
Novartis confirmed on Monday, June 12, that it has agreed to a deal that will merge its new subsidiary with Chinook Therapeutics. According to Reuters, the transaction between the companies is expected to be completed by the second half of this year.
Then again, the merger deal is still subject to customary closing conditions. It was also mentioned that this move is completely in accordance with Novartis’ strategy to point its attention to innovative medicines. The buyout will also expand the company’s renal portfolio.
The Swiss pharma further explained that it will acquire the Seattle, Washington-headquartered clinical biotech firm with two high-value, late-stage medicines in development for rare, chronic kidney diseases. Under the contract, shareholders of Chinook will receive $3.2 billion, which is equivalent to $40 per share, in cash. Novartis added that shareholders will also get a contingent value right worth up to $300 million, which will depend on some regulatory achievements.
Meanwhile, Chinook Therapeutics is looking to report data from the last phase of research for its experimental oral drug called Atrasentan, which is used to treat a kidney disease known as IgAN, in the Q4 of 2023. It is currently working on another experimental injectable version of the IgAN treatment called Zigakibart. A late-stage trial for these treatments is set to begin in the third quarter of this year.
“IgA Nephropathy is a devastating disease mostly affecting young adults and potentially leading to dialysis or kidney transplantation,” Novatis’ chief executive officer, Vas Narasimhan, M.D., said in a press release. “We are excited by this unique opportunity to address one of society’s most challenging healthcare issues, with the potential to bring additional much-needed treatment options to patients. We look forward to closing the deal, to a smooth transition for Chinook employees and to welcoming them to Novartis.”
Photo by: Novartis Media Gallery
